paraganglioma
Information
- Disease name
- paraganglioma
- Disease ID
- DOID:0050773
- Description
- "A pheochromocytoma that arises in extraadrenal sympathetic ganglia." [url:https\://en.wikipedia.org/wiki/Paraganglioma, url:https\://ghr.nlm.nih.gov/condition/hereditary-paraganglioma-pheochromocytoma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| SDHB | 1 | 17,018,722 | 17,054,032 | 16 |
| SETD2 | 3 | 47,016,436 | 47,164,113 | 10 |
| SDHD | 11 | 112,086,873 | 112,095,794 | 8 |
| SDHA | 5 | 218,320 | 257,082 | 8 |
| RET | 10 | 43,077,069 | 43,130,351 | 4 |
| CSDE1 | 1 | 114,716,916 | 114,757,983 | 2 |
| SDHB | 1 | 17,018,722 | 17,054,032 | 2 |
| VEGFA | 6 | 43,770,707 | 43,784,609 | 2 |
| EDN2 | 1 | 41,478,775 | 41,484,683 | 2 |
| SDHAF2 | 11 | 61,430,124 | 61,446,733 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04711135 | Active, not recruiting | Phase 2 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | August 31, 2022 | May 7, 2029 |
| NCT04187404 | Active, not recruiting | Phase 1/Phase 2 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | July 23, 2020 | November 30, 2025 |
| NCT04400474 | Active, not recruiting | Phase 2 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | October 7, 2020 | March 2024 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT02961491 | Approved for marketing | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | |||
| NCT01377532 | Approved for marketing | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | |||
| NCT01590680 | Available | Expanded Access Protocol Using 131I-MIBG | |||
| NCT00458952 | Completed | Phase 1/Phase 2 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | April 2007 | June 2011 |
| NCT01022515 | Completed | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma | November 2008 | December 2013 | |
| NCT01204476 | Completed | Phase 1 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | October 2010 | |
| NCT01560260 | Completed | Phase 2 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | March 2012 | October 2015 |
| NCT00188019 | Completed | N/A | Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers | November 2005 | November 2013 |
| NCT01967576 | Completed | Phase 2 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | October 19, 2013 | December 1, 2020 |
| NCT05082311 | Completed | Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma | January 19, 2019 | January 31, 2022 | |
| NCT00339131 | Completed | Phase 1 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | June 2006 | January 2007 |
| NCT03176693 | Completed | Phase 3 | Preoperative Alpha Blockade for Pheochromocytoma | May 5, 2017 | October 10, 2021 |
| NCT00843037 | Completed | Phase 2 | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | February 2009 | March 14, 2022 |
| NCT01413503 | Completed | Phase 2 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | May 1991 | May 2009 |
| NCT02431715 | No longer available | 18F-FDOPA PET in Neuroendocrine Tumours | |||
| NCT01838187 | No longer available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | |||
| NCT06045260 | Not yet recruiting | Phase 2 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC | October 2023 | January 2027 |
| NCT06377033 | Not yet recruiting | N/A | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | May 1, 2024 | June 30, 2027 |
| NCT06444607 | Not yet recruiting | Hereditary Pheochromocytoma Assessment of Tumour Immunologies | June 1, 2024 | June 1, 2029 | |
| NCT06233903 | Not yet recruiting | Phase 2 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | July 2024 | March 2025 |
| NCT04788927 | Not yet recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study | October 1, 2023 | September 30, 2027 | |
| NCT05885386 | Recruiting | Phase 2 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | April 1, 2023 | October 1, 2025 |
| NCT03160274 | Recruiting | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | October 19, 2005 | December 31, 2030 | |
| NCT03206060 | Recruiting | Phase 2 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | October 10, 2017 | January 1, 2027 |
| NCT03344016 | Recruiting | N/A | Multicenter Pheochromocytoma and Paraganglioma Evaluation | November 1, 2017 | November 1, 2040 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT03839498 | Recruiting | Phase 2 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | January 22, 2019 | January 2024 |
| NCT03946527 | Recruiting | Phase 2 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | June 17, 2019 | December 2023 |
| NCT04017104 | Recruiting | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | November 1, 2019 | August 1, 2024 | |
| NCT04081701 | Recruiting | Phase 4 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | September 4, 2019 | December 31, 2038 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT05069220 | Recruiting | Early Phase 1 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | September 1, 2021 | December 2026 |
| NCT05142241 | Recruiting | Phase 2 | Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial | July 11, 2022 | April 15, 2026 |
| NCT05233878 | Recruiting | Prognostic's Factors of Head and Neck Paragangliomas Evolution | July 19, 2022 | July 2026 | |
| NCT05418907 | Recruiting | Exendin PET/CT for Imaging of Paragangliomas | June 1, 2022 | December 1, 2024 | |
| NCT05636540 | Recruiting | Early Phase 1 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | July 1, 2023 | December 31, 2025 |
| NCT05636618 | Recruiting | Phase 1/Phase 2 | Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | September 27, 2023 | January 31, 2028 |
| NCT05702944 | Recruiting | Phase 4 | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | January 18, 2023 | October 31, 2024 |
| NCT05883085 | Recruiting | Phase 2 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | May 1, 2022 | May 1, 2024 |
| NCT06155734 | Recruiting | Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green | November 11, 2023 | February 20, 2024 | |
| NCT06440122 | Recruiting | The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs) | May 31, 2024 | December 31, 2024 | |
| NCT02177773 | Terminated | Phase 1/Phase 2 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies | June 23, 2014 | August 7, 2017 |
| NCT00911729 | Terminated | Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma | April 2009 | ||
| NCT05948137 | Terminated | F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma | September 21, 2017 | June 30, 2020 | |
| NCT04605848 | Terminated | N/A | Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) | July 3, 2020 | October 20, 2023 |
| NCT03165721 | Terminated | Phase 2 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | August 16, 2017 | February 24, 2020 |
| NCT01340794 | Terminated | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | May 2011 | November 2014 |
| NCT04891081 | Unknown status | Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | November 1, 2019 | June 9, 2021 | |
| NCT01373736 | Unknown status | Phase 3 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | ||
| NCT00874614 | Unknown status | Phase 2 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | June 4, 2009 | February 2021 |
| NCT05451134 | Unknown status | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma | June 30, 2022 | July 20, 2022 | |
| NCT04573816 | Unknown status | Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma | October 8, 2020 | November 1, 2023 | |
| NCT01941849 | Withdrawn | Phase 1 | Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | October 2014 | December 2015 |
| NCT04276597 | Withdrawn | Phase 2 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | March 4, 2020 | July 15, 2021 |
| NCT03923257 | Withdrawn | Phase 1/Phase 2 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | August 4, 2020 | June 3, 2021 |
- Disase is a (Disease Ontology)
- DOID:0050771
- Cross Reference ID (Disease Ontology)
- ICDO:8680/3
- Cross Reference ID (Disease Ontology)
- MESH:D010235
- Cross Reference ID (Disease Ontology)
- MIM:115310
- Cross Reference ID (Disease Ontology)
- MIM:168000
- Cross Reference ID (Disease Ontology)
- MIM:601650
- Cross Reference ID (Disease Ontology)
- MIM:605373
- Cross Reference ID (Disease Ontology)
- MIM:614165
- Cross Reference ID (Disease Ontology)
- MIM:PS168000
- Cross Reference ID (Disease Ontology)
- NCI:C3308
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:302833002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0030421
- Exact Synonym (Disease Ontology)
- chemodectoma
- Exact Synonym (Disease Ontology)
- glomus body tumor
- HPO alt_id (Human Phenotype Ontology)
- HP:0002670
- HPO alt_id (Human Phenotype Ontology)
- HP:0003004
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002668
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010235